Galera Therapeutics
Galera Therapeutics is dedicated to developing novel therapies to improve treatment outcomes for patients with cancer, particularly breast cancer. They focus on innovative scientific approaches, including superoxide dismutase mimetics and nitric oxide synthase inhibitors, to enhance the efficacy of existing treatments and reduce suffering. Their mission is to advance patient care by easing suffering and elevating quality of life.
Industries
Nr. of Employees
small (1-50)
Galera Therapeutics
Malvern, Pennsylvania, United States, North America
Products
SOD mimetic investigational therapy for reduction of chemoradiotherapy-induced oral mucositis
An investigational small-molecule SOD mimetic evaluated in randomized clinical trials to reduce severe oral mucositis in patients receiving chemoradiotherapy for head and neck cancer; studied across Phase 1–3 trials.
SOD mimetic investigational therapy for combination with SBRT in NSCLC and pancreatic cancer
An investigational SOD mimetic being developed for use in combination with stereotactic body radiation therapy for indications including non‑small cell lung cancer and pancreatic cancer; referenced in regulatory and pipeline communications including orphan designation for pancreatic cancer.
GC4419
GC4711 is a selective small molecule dismutase mimetic being developed to increase the anti-cancer effect of radiation, specifically to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer and non-small cell lung cancer.
Avasopasem manganese
Avasopasem manganese is a drug under FDA priority review for the treatment of radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer undergoing standard-of-care treatment. It aims to reduce the incidence, severity, and duration of SOM and has shown potential to reduce cisplatin-induced chronic kidney disease.
Tilarginine
Tilarginine is L-NMMA (NG-monomethyl-L-arginine), a nitric oxide synthase (NOS) inhibitor, administered IV over 2 hours, with Amlodipine pretreatment.
SOD mimetic investigational therapy for reduction of chemoradiotherapy-induced oral mucositis
An investigational small-molecule SOD mimetic evaluated in randomized clinical trials to reduce severe oral mucositis in patients receiving chemoradiotherapy for head and neck cancer; studied across Phase 1–3 trials.
SOD mimetic investigational therapy for combination with SBRT in NSCLC and pancreatic cancer
An investigational SOD mimetic being developed for use in combination with stereotactic body radiation therapy for indications including non‑small cell lung cancer and pancreatic cancer; referenced in regulatory and pipeline communications including orphan designation for pancreatic cancer.
GC4419
GC4711 is a selective small molecule dismutase mimetic being developed to increase the anti-cancer effect of radiation, specifically to augment the anti-cancer efficacy of stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer and non-small cell lung cancer.
Avasopasem manganese
Avasopasem manganese is a drug under FDA priority review for the treatment of radiotherapy-induced severe oral mucositis (SOM) in patients with head and neck cancer undergoing standard-of-care treatment. It aims to reduce the incidence, severity, and duration of SOM and has shown potential to reduce cisplatin-induced chronic kidney disease.
Tilarginine
Tilarginine is L-NMMA (NG-monomethyl-L-arginine), a nitric oxide synthase (NOS) inhibitor, administered IV over 2 hours, with Amlodipine pretreatment.
Services
Intake, evaluation, and case-by-case consideration of requests for pre‑approval access to investigational therapies submitted by licensed treating physicians; includes acknowledgement timelines and defined evaluation criteria.
Intake, evaluation, and case-by-case consideration of requests for pre‑approval access to investigational therapies submitted by licensed treating physicians; includes acknowledgement timelines and defined evaluation criteria.
Expertise Areas
- Oncology small-molecule drug development
- Clinical trial management in oncology
- Translational research and biomarker analysis
- Combination therapy development (radiation + small molecule)
Key Technologies
- Superoxide dismutase (SOD) mimetic chemistry
- Nitric oxide synthase (NOS) inhibition
- Small-molecule medicinal chemistry
- Combination therapy with stereotactic body radiation therapy (SBRT)